Investment Rating - The report assigns an "Overweight" (OW) rating to Akeso with a price target of HK$99.00 by December 2025 [2][5]. Core Insights - Akeso's AK104, a PD-1/CTLA-4 bispecific antibody, has received approval in China for first-line treatment of persistent, recurrent, or metastatic cervical cancer, which is expected to significantly boost sales in China [1][4]. - The report anticipates a global development plan for AK104 to be announced in the second half of 2025, which could attract investor interest [1][4]. - Upcoming catalysts include sales figures for AK104 and AK112, the potential global development plan announcement, and detailed data from the HARMONi studies [4][5]. Summary by Sections Approval and Efficacy - AK104's approval is based on strong results from the Phase 3 COMPASSION-16 study, showing a median overall survival (mOS) not reached in the AK104+chemo cohort compared to 22.8 months in the control group, and a median progression-free survival (mPFS) of 12.7 months versus 8.1 months [4]. Market Potential - The report estimates that AK104 could generate approximately RMB 6 billion in peak sales in China, while AK112 is expected to achieve over RMB 5 billion in peak sales in non-small cell lung cancer (NSCLC) [5]. Valuation - The price target of HK$99.00 is based on a discounted cash flow (DCF) valuation, assuming a terminal growth rate of 3.0% and a weighted average cost of capital (WACC) of 9.4% [6].

Investment Rating - The report maintains a Neutral rating for HUTCHMED (HCM) with a 12-month price target of $18 for the ADR listed in the US, indicating a potential upside of 32.4% from the current price of $13.60 [12][14]. Core Insights - Increased investor focus is expected on savolitinib following data presentations at ASCO, with the company highlighting severe under-detection of MET amplification when using NGS testing compared to FISH testing [1][2]. - The company’s internal unpublished data suggests that only about 30% of patients who test positive for MET amplification via FISH would also test positive using the NGS method [2]. - The global Phase 3 SAFRON study of savolitinib in combination with osimertinib will offer patients the option of two companion diagnostics: FISH and IHC methods [2]. Summary by Sections MET Amplification Testing - Testing for MET amplification is crucial for patient selection, with a cross-study analysis indicating that NGS testing severely under-detects the biomarker compared to FISH [2]. - The MARIPOSA-2 study detected MET amplification in 14% of patients using ctDNA NGS, while the SACHI study showed approximately 30% detection using tissue FISH [5]. Clinical Efficacy - The SACHI study demonstrated a median progression-free survival (PFS) of 8.2 months for the savolitinib plus osimertinib combination compared to 4.5 months for chemotherapy, with a statistically significant hazard ratio of 0.34 [5][6]. - For patients previously treated with a 3rd-generation EGFR TKI, the median PFS was 6.9 months for the combination arm versus 3.0 months for chemotherapy, also showing a significant difference [6]. Safety Profile - The SAVANNAH study indicated a promising PFS curve separation with a manageable safety profile, although adverse events leading to dose interruption of savolitinib occurred in approximately 48% of patients [9].

Investment Rating - The report maintains an "Overweight" rating on Zai Lab (ZLAB) shares, indicating a positive outlook on the stock's performance relative to its peers [2][4]. Core Insights - The ZL-1310 ASCO phase 1a/1b update demonstrates a compelling efficacy and safety profile, highlighting its differentiated potential in treating extensive-stage small cell lung cancer (ES-SCLC) [4]. - The 1.6 mg/kg cohort shows a 79% unconfirmed overall response rate (ORR) and a 100% disease control rate (DCR) in patients with one prior line of therapy, suggesting strong efficacy [4]. - The report anticipates that Zai Lab will initiate a pivotal trial in second-line SCLC later this year, which could further validate the drug's potential [4]. - The report estimates that assuming approximately $500 million in net sales/royalties to Zai Lab, this could add mid-single digits to the valuation of ZLAB shares [4]. Summary by Sections Efficacy and Safety Profile - The ZL-1310 trial data indicates a 67% unconfirmed ORR and a 97% DCR in the overall population of 33 patients [4]. - The safety profile is described as clean, with no discontinuations and Grade 3+ treatment-related adverse events (TRAEs) at 6%, primarily consisting of anemia (2%) and neutropenia (4%) [4]. Competitive Landscape - The report notes that Imdelltra (tarlatamab) has a ~40% ORR in relapsed/refractory ES-SCLC, positioning ZL-1310 favorably in comparison [4]. Future Outlook - Zai Lab's existing commercial franchise and upcoming product launches, along with a growing internal pipeline including ZL-1310, support the reiterated Overweight rating [4].

Investment Rating - The report maintains a "Buy" rating for Miniso, with a 12-month price target of $23.10 for ADR and HK$45.00 for H-share, indicating an upside potential of 34.5% and 33.7% respectively [14][17]. Core Insights - Miniso is expected to experience sequential sales growth acceleration, with management confident in margin improvement and a peak in DTC-related expenses in the first half of the year [1][2]. - Same-store sales growth (SSSG) turned positive in May for Miniso China, and positive trends were also observed in the US and other overseas markets [1][7]. - The company plans to enhance its product offerings, focusing on both intellectual property (IP) products and value-for-money lifestyle products, with localized designs for overseas markets [1][10]. - Management aims to expand to over 1,000 stores in the US market, targeting a 20% operating profit margin in the mid to long term, despite potential short-term volatility [1][11]. Summary by Sections Sales Growth and Guidance - For Q2 2025, Miniso China is expected to achieve low teens percentage sales growth, while Miniso Overseas and Top Toy are projected to grow by 25%-30% and 70%-80% year-over-year respectively [8]. - If the SSSG recovery trend continues, operating profits are likely to turn positive in Q3, with full-year adjusted operating profits targeted at RMB 3.6 billion to RMB 3.8 billion [8]. Product Strategy - The company is enhancing its IP product quality and focusing on localized designs for international markets, while also improving the merchandising of value-for-money products [10][12]. - A dedicated zone for top-selling products has been added to increase conversion rates, and inventory management will be prioritized to avoid stockouts of best-sellers [11]. Market Performance - Year-to-date, Miniso China's SSSG has shown improvement, with positive trends in the US market and other overseas markets noted in April and May [7][11]. - The US market has seen the opening of approximately 20 new stores, primarily in plaza locations, achieving double-digit operating profit margins despite being in a low season [11]. Long-term Outlook - Miniso is positioned to become a leading global IP retailer, with catalysts for share price growth including accelerated store expansion, improved SSSG, and higher contributions from IP products [14]. - The market currently underappreciates Miniso's potential adjusted net income compound annual growth rate (CAGR) of nearly 20% from 2024 to 2026, excluding contributions from Yonghui [14].

Investment Rating - The report maintains an "Overweight" (OW) rating for Laopu Gold with a price target of HK$1,149.00 for December 2025, up from a prior target of HK$1,111.00 [4][26]. Core Insights - Laopu Gold is positioned as a niche luxury brand in the China heritage gold sector, with a market share of 2% as of 2023 and a strong focus on tier 1 and new tier 1 cities, which account for over 85% of its sales [10][26]. - The company is expected to achieve a compound annual growth rate (CAGR) of 61% in sales and 68% in net profit from 2025 to 2027, driven by the growth of the heritage gold segment, store expansion, and enhanced brand equity [10][26]. - Laopu plans to open at least eight new boutiques in 2025, surpassing the seven opened in 2024, and will continue refreshing existing boutiques [7][10]. Summary by Sections Sales and Revenue Projections - Revenue estimates for 2025 have been raised from Rmb 18,780 million to Rmb 19,973 million, and for 2026 from Rmb 26,172 million to Rmb 28,061 million [5]. - The company targets mid-term sales per shopping mall to reach Rmb 1 billion by 2025, significantly higher than the Rmb 300 million expected in 2024 [10]. Boutique Expansion and Strategy - Laopu's expansion strategy includes opening its first overseas boutique in Singapore and a differentiated product offering in Tokyo targeting non-Chinese customers [10][26]. - The company plans to refresh at least four existing boutiques in 2025, maintaining the same level as in 2024 [7][10]. Market and Pricing Dynamics - Laopu's management is optimistic about the upward trend in gold prices, with expectations of a 41% increase in 2025 and 21% in 2026, which will support further penetration into target consumer groups [7][20]. - The company has implemented a price adjustment policy to maintain a gross profit margin (GPM) target of over 40%, with expectations of 1-2 additional price increases in 2025 [7][10]. Financial Metrics and Valuation - The report projects a significant increase in adjusted earnings per share (EPS) from Rmb 9.47 in 2025 to Rmb 24.14 in 2026, reflecting a growth rate of 154.8% [9][10]. - The DCF-based price target of HK$1,149 implies a forward P/E ratio of 32x for 2025 [27]. Performance Drivers - Laopu's strong performance is attributed to its high single-store sales, pricing premium over local brands, and a robust retail experience that enhances customer loyalty [10][26]. - The company is expected to benefit from a favorable product mix and operational leverage, leading to a net margin expansion of 1.5 percentage points in 2025 [13].

Investment Rating - The report assigns a "Buy" rating for CSPC Pharma with a 12-month price target of HK$8.74, indicating an upside potential of 14.7% from the current price of HK$7.62 [13][14]. Core Insights - The report highlights that CSPC Pharma experienced a revenue decline of 22% in Q1, primarily due to a high base in Q1 2024, ongoing pressure from volume-based procurement (VBP), and a 12.5% price cut for NBP injection [1]. - Despite the revenue miss, earnings showed resilience, supported by out-licensing income and significant expense cuts, particularly in selling expenses [1]. - Management has revised its guidance for 2025, focusing on sequential improvement rather than positive sales growth, and plans to pursue three more business development (BD) deals with a potential total deal size exceeding US$5 billion [2][8]. Summary by Sections Revenue and Earnings Performance - CSPC Pharma's sales in Q1 declined by 22% year-on-year, with finished drug sales down 27% year-on-year [1]. - Earnings for Q1 were reported at Rmb1.5 billion, an 8% decrease year-on-year, but were bolstered by Rmb718 million from out-licensing [1]. - Core earnings, excluding BD income, are estimated to have declined by approximately 45% year-on-year [1]. Business Development and Licensing - The company is actively negotiating three potential BD deals, with one expected to close in June, focusing on SYS6010 (EGFR ADC) and other technology collaborations [2]. - In Q1, CSPC Pharma booked US$40 million from the AZ deal and US$60 million from the BeOne deal, with expectations of over Rmb1 billion in additional income from new deals throughout the year [2]. Clinical Development and Pipeline - SYS6010 is prioritized for clinical development, with ongoing phase 3 studies for NSCLC and plans for further trials in various solid tumors [3][7]. - The company is preparing for pivotal studies outside China and aims to apply for breakthrough designation for certain assets [7]. Shareholder Returns and Incentives - CSPC Pharma plans to utilize operational cash flow for R&D and higher dividends, with a share buyback target of up to HK$5 billion over the next 24 months [8]. - A share-based incentive program is set to cover 200-300 key staff, with additional coverage planned for the second half of 2025 [8]. Financial Projections - Earnings estimates have been revised down by 7.7% for 2025 due to lower-than-expected finished drug sales, but the price target has increased from HK$7.84 to HK$8.74 [9]. - Revenue projections for 2025 are set at Rmb30.1 billion, with expectations of gradual recovery in subsequent years [14].

Investment Rating - The report maintains a "Buy" rating for Miniso, with a 12-month price target of $23.40 for ADR and HK$46.00 for H-share, indicating an upside potential of 27.9% and 33.1% respectively [14][17]. Core Insights - Management is confident in achieving revenue growth acceleration in 2025, targeting a year-over-year increase of 23% compared to 2024, with a focus on low teens percentage growth in Miniso China and around 40% growth in overseas markets [1][8]. - Despite expected margin pressure in the short term, management anticipates a return to positive operating profit growth by the third quarter of 2025, with a narrowing of margin contraction [1][2]. - The company plans to close 300-400 underperforming stores in China, with expectations of a return to net store count growth in the second half of 2025 [1][12]. Summary by Sections Financial Performance - For 2025, Miniso aims for revenue of Rmb20,554 million, with an operating profit (OP) target of Rmb3.6 billion to Rmb3.8 billion, compared to Rmb3.2 billion in the previous year [17]. - In 2Q25, management expects topline growth of 18%-21%, with specific growth rates of low teens for Miniso China and 25%-30% for overseas markets [8]. Market Strategy - The company is focusing on optimizing its product offerings in the US, with IP-related products making up 60-70% of sales, and plans to increase local sourcing to mitigate tariff impacts [12][15]. - Miniso's store expansion strategy includes targeting 80-100 net new store openings in 2025, with a significant portion being DTC stores [10][11]. Operational Efficiency - Management noted that logistics costs have declined, and there is potential for cost savings through improved store productivity and geographical concentration of store openings [10][12]. - The average payback period for new stores is reported to be 15-18 months, with daily sales averaging nearly Rmb10,000, significantly above the breakeven point [13].

Investment Rating - The report initiates coverage on CATL H-shares with a Buy rating and sets a target price of HK$425. The A-share target price is raised to Rmb391 from Rmb362 [1][5]. Core Viewpoints - CATL is transforming into a leader in new energy technology and solutions, well-positioned to benefit from long-term growth in the global electric vehicle (EV) and energy storage system (ESS) battery markets [1][5]. - Despite a slowdown in global battery demand growth, the effective utilization ratio in the battery industry is expected to improve due to slower capacity expansion, with CATL's capacity utilization projected to exceed the industry average [2][10]. - The impact of US tariffs and geopolitical risks on CATL is expected to be limited due to its low exposure to the US market [3][18]. - Margins in the ESS battery segment are anticipated to rebound in the latter half of 2025 as sales to overseas markets increase [4][20]. Summary by Sections Addressing Investor Concerns - **Global Battery Demand Growth**: Expected to slow to 25% in 2025 and 26% in 2026, down from 40% in 2023 and 30% in 2024. The global battery effective utilization ratio is projected to rise to 58%/59% in 2025/26 from 57% in 2024 [2][10]. - **Impact of US Tariffs**: CATL's battery shipments to the US fell to 2-3% of total shipments in 1Q25, indicating limited exposure and impact from tariffs [3][18]. - **Unit GP and EBIT Pressure**: CATL's margins are expected to recover in 2-4Q25E with an increase in overseas sales, which typically have higher margins [4][20]. Company Description - CATL is the largest battery producer globally, specializing in rechargeable lithium-ion batteries for EVs and ESS, with a sales volume of 381GWh for EVs and 93GWh for ESS in 2024, reflecting a year-on-year growth of 19% and 35% respectively [41]. Investment Strategy - The report emphasizes CATL's strategic positioning in the new energy sector and its potential to capitalize on the growing demand for EVs and ESS, reinforcing its status as a top pick in the battery supply chain [5][29]. Valuation - The target price for CATL A-shares is set at Rmb391, based on a 16.6x EV/EBITDA for 2025, while the H-share target price of HK$425 implies a 28.2x P/E for 2025 and 22.4x for 2026 [5][29].

Investment Rating - The report maintains a "Buy" rating for Miniso (MNSO) with a 12-month price target of $23.40, indicating an upside potential of 5.5% from the current price of $22.19 [1]. Core Insights - Miniso reported a 19% year-over-year revenue growth in 1Q25, slightly above guidance, but adjusted operating profit declined by 5% year-over-year, missing expectations due to higher contributions from lower-margin direct-to-consumer (DTC) sales and new store openings [1][2]. - Management remains optimistic about top-line growth for 2025, but has tempered expectations regarding margins due to the ongoing transition to a DTC model [1][2]. - The company aims for a positive same-store sales growth (SSSG) recovery, with management targeting double-digit growth in China and a 40% year-over-year increase in overseas markets [19][20]. Summary by Sections Earnings Review - In 1Q25, total sales reached Rmb 4.4 billion, reflecting a 19% year-over-year increase, with overseas sales growing by 30% year-over-year [29]. - The adjusted net profit was Rmb 587 million, which was 6% lower than expectations, primarily due to lower-than-expected operating profit [32][34]. Financial Forecasts - Revenue forecasts for 2025-2027 have been adjusted slightly downward, with total sales projected at Rmb 20.55 billion for 2025, reflecting a 20.9% growth [37]. - The adjusted net profit for 2025 is now estimated at Rmb 2.22 billion, a 14.7% decrease from previous estimates [37]. Operational Insights - The company closed 111 stores in Mainland China during 1Q25, which was below expectations, while opening 95 stores overseas [31]. - Management highlighted that the DTC model will continue to exert pressure on margins in the near term, but expects improvements in operational efficiency to mitigate this impact [19][20]. Market Strategy - Miniso's strategy includes a focus on increasing the number of larger format stores and enhancing same-store sales productivity, with plans to open fewer stores than previously targeted [25]. - The company is also investing in its IP strategy, which has shown positive market feedback, particularly in the toy category, which accounted for 30% of sales in 1Q25 [27][28].

Investment Rating - The report initiates coverage on Pop Mart with an "Overweight" (OW) rating and sets a price target of HK$250 for June 2026, which implies a PEG of 1.3x and a P/E of 32.6x for 2026 [1][4][9]. Core Insights - Pop Mart is positioned as a leader in China's rapidly growing IP merchandise market, boasting a portfolio of over 100 owned and licensed IPs, 521 retail stores, and 2,472 roboshops across more than 30 countries. The company is also leveraging major online platforms for sales [1][8]. - The report highlights two main reasons for favoring Pop Mart: its strong IP offerings, particularly the rising 'super IP' Labubu, and its ambitious global expansion plans, with overseas sales projected to grow at a 42% CAGR from 2025 to 2027, contributing 65% of total sales by 2027 [1][8]. - Forecasts indicate a sales CAGR of 44% and an earnings CAGR of 56% from 2024 to 2027, driven by strong IP, store openings, improved productivity, and margin expansion [1][8]. Summary by Sections Market Position and Strategy - Pop Mart leads the IP merchandise market in China, with significant growth potential in overseas markets, particularly in North America and Europe, where sales surged 480% year-over-year in Q1 2025 [5][8]. - The company aims to capitalize on its strong IP portfolio and global expansion strategy, with expectations of overseas sales growth outpacing domestic growth [5][8]. Financial Projections - The report projects revenue growth from Rmb 13,038 million in FY24 to Rmb 39,335 million in FY27, with an adjusted EBITDA margin increasing from 38.5% to 43.9% over the same period [7][8]. - Adjusted EPS is expected to grow from 2.42 in FY24 to 9.13 in FY27, reflecting a strong upward trajectory in profitability [7][8]. Valuation Metrics - The price target of HK$250 is based on a PEG ratio of 1.3x, which is a 20% discount compared to similar companies in the market [9]. - The DCF-based fair value estimate ranges from HK$226 to HK$327, indicating a favorable valuation compared to peers [9]. Competitive Analysis - The report compares Pop Mart with established players like Sanrio, highlighting Pop Mart's rapid growth in brand recognition and market share, particularly with its IP Labubu, which is seen as a potential competitor to Hello Kitty [5][17][29]. - The analysis indicates that while Sanrio has a long-established presence, Pop Mart's innovative marketing and product strategies are driving significant consumer interest and engagement [5][29].